ProMIS Neurosciences, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2025


	Years Ended December 31,
	2025			2024
Operating Expenses:
PMN310 development program costs	$	30,226,059		$	8,275,268
Other non-employee research and development costs		885,907			772,501
Employee costs		5,051,277			3,336,580
Other general and administrative costs		4,004,065			4,443,129
Net Operating Loss:	$	40,167,308		$	16,827,478
Other segment items^(a)		(448,161)			(19,606,351)
Net Loss (Income):	$	39,719,147		$	(2,778,873)

Reconciliation of Profit or Loss
Adjustments and reconciling items		—			—
Consolidated Net Loss (Income):	$	39,719,147		$	(2,778,873)

^(a)Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense